Nav: Home

Computational platform optimizes multiple myeloma treatments

August 08, 2018

Masturah Bte Mohd Abdul Rashid and colleagues have developed a new platform that optimizes drug combinations for the treatment of multiple myeloma (MM), an incurable blood cancer. The computational platform, named QPOP, could one day help improve clinical outcomes in patients with MM that has become resistant to standard therapies. Combination therapies have become a pillar of many cancer treatment plans because they can be more effective than single therapies that only disrupt one molecular pathway. MM - a blood cancer involving malignant plasma cells - is frequently treated with combination therapies that include bortezomib, a first-line drug with promising response rates. However, most MM patients end up relapsing due to the development of resistance against bortezomib, highlighting a need to identify secondary combination treatments that can overcome or forestall therapeutic resistance. Rashid and colleagues developed a tool named the quadratic phenotypic optimization platform (QPOP), which approximates biological responses to therapies using advanced mathematical equations. Unlike conventional models, QPOP doesn't require predetermined information about the mechanisms or composition of a drug to optimize treatments. The authors tested their platform with 128 different combinations of 14 FDA-approved anticancer drugs, and found QPOP was able to identify effective combinations and dosages against bortezomib-resistant MM. A combination of the approved drugs mitomycin C and decitabine decreased tumor size and prolonged survival in a mouse model of bortezomib-resistant MM, suggesting the platform could be a useful tool in efforts to identify promising drug combinations for MM patients.The authors also say that further studies will be needed to determine if QPOP could be applied to the treatment of other blood cancers.
-end-


American Association for the Advancement of Science

Related Multiple Myeloma Articles:

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response.
Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.
New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.
Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.
New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.
BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.
Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.
NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma
Celgene Corporation and bluebird bio announce results from ongoing multicenter Phase 1 study of bb2121 anti-BCMA CAR T cell therapy in patients with multiple myeloma published in the New England Journal of Medicine.
Multiple myeloma: DNA rearrangement may predict poor outcomes
In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide.
Computational platform optimizes multiple myeloma treatments
Masturah Bte Mohd Abdul Rashid and colleagues have developed a new platform that optimizes drug combinations for the treatment of multiple myeloma (MM), an incurable blood cancer.
More Multiple Myeloma News and Multiple Myeloma Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Biology Of Sex
Original broadcast date: May 8, 2020. Many of us were taught biological sex is a question of female or male, XX or XY ... but it's far more complicated. This hour, TED speakers explore what determines our sex. Guests on the show include artist Emily Quinn, journalist Molly Webster, neuroscientist Lisa Mosconi, and structural biologist Karissa Sanbonmatsu.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

The Wubi Effect
When we think of China today, we think of a technological superpower. From Huweai and 5G to TikTok and viral social media, China is stride for stride with the United States in the world of computing. However, China's technological renaissance almost didn't happen. And for one very basic reason: The Chinese language, with its 70,000 plus characters, couldn't fit on a keyboard.  Today, we tell the story of Professor Wang Yongmin, a hard headed computer programmer who solved this puzzle and laid the foundation for the China we know today. This episode was reported and produced by Simon Adler with reporting assistance from Yang Yang. Special thanks to Martin Howard. You can view his renowned collection of typewriters at: antiquetypewriters.com Support Radiolab today at Radiolab.org/donate.